Resource Summary Report

Generated by SPARC SAWG on Aug 12, 2026

Brilliant Violet 421(TM) anti-mouse CD3

RRID:AB_2562553
Type: Antibody

Proper Citation

BioLegend Cat# 100228, RRID:AB_2562553

Antibody Information

URL: http://antibodyregistry.org/AB_2562553

Proper Citation: BioLegend Cat# 100228, RRID:AB_2562553

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, ICC

Antibody Name: Brilliant Violet 421(TM) anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_2562553

Vendor: BioLegend

Catalog Number: 100228

Alternative Catalog Numbers: 100227

Record Creation Time: 20250820T001813+0000

Record Last Update: 20250820T075506+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse CD3.

No alerts have been found for Brilliant Violet 421(TM) anti-mouse CD3.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 39 mentions in open access literature.

Listed below are recent publications. The full list is available at SPARC SAWG .

Bosma DMT, et al. (2026) Requirements for development of T helper 1 and T follicular helper cells from a common precursor. Cell reports, 45(5), 117296.

Yu X, et al. (2026) Bacterial vesicles from intratumoral L. salivarius enhance PD-1 blockade via FPR1-mediated macrophage polarization in gastric cancer. Cell reports. Medicine, 7(2), 102621.

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment. Cancer immunology research, 14(5), 718.

Li Z, et al. (2026) Insufficient erythrocyte-derived S1P: A pathogenic driver and diagnostic biolipid for tumor progression. iScience, 29(4), 115216.

Park C, et al. (2026) A Rasa3-G?i signaling axis orchestrates B lymphocyte trafficking into and through lymphoid organs. Cell reports, 45(4), 117243.

Shamskhou EA, et al. (2026) Monocytic niches escape T cell surveillance and promote Mycobacterium tuberculosis persistence in lymph nodes. Immunity.

Silberstein E, et al. (2026) CCL signaling drives T Cell-Macrophage crosstalk in the mouse colon during chronic Trypanosoma cruzi infection. iScience, 29(7), 116611.

Liu S, et al. (2026) ?-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer. Cell, 189(6), 1701.

Zeng Q, et al. (2025) Gut microbiota-driven pathogenic Th17 cells mediated autoimmune epididymo-orchitis in a mouse model of colitis. iScience, 28(5), 112508.

Weller C, et al. (2025) Translation dysregulation in cancer as a source for targetable antigens. Cancer cell, 43(5), 823.

Wei H, et al. (2025) AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity. Cell metabolism, 37(5), 1103.

Mout R, et al. (2025) Design of soluble Notch agonists that drive T cell development and boost immunity. Cell.

Mayerhofer C, et al. (2025) OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis. Cell metabolism.

Guruprasad P, et al. (2025) Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy. Nature protocols.

Zhong Y, et al. (2025) Photoconverted cells allow rapid assessment of vaccine adjuvant potency in mice. iScience, 28(7), 112774.

Saini M, et al. (2025) StealTHY: An immunogen-free CRISPR platform to expose concealed metastasis regulators in immunocompetent models. Cell, 188(26), 7591.

Sonehara K, et al. (2025) Whole-genome sequencing reveals rare and structural variants contributing to psoriasis and identifies CERCAM as a risk gene. Cell genomics, 100978.

Wofford W, et al. (2024) Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response. Cell reports, 43(8), 114532.

Shapir Itai Y, et al. (2024) Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell, 187(2), 375.

Mei D, et al. (2024) Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models. Journal for immunotherapy of cancer, 12(9).